AZD2461: Novel PARP Inhibitor for Breast Cancer Research

Executive Summary:

• AZD2461 is a next-generation PARP inhibitor with an IC50 of 5 nM against PARP-1, demonstrating high potency in cellular and in vivo models (ApexBio).
• It induces G2 phase cell cycle arrest and reduces S phase proportion in breast cancer cell lines (Schwartz 2022).
• AZD2461 exhibits lower affinity for P-glycoprotein (Pgp) than olaparib, potentially overcoming clinically relevant drug resistance (ApexBio).
• In vivo, AZD2461 prolongs relapse-free survival and is well-tolerated in BRCA1-mutated tumor models (Schwartz 2022).
• Optimal use requires precise dosing (5–50 μM) and incubation (48–72 h) in cell culture (ApexBio).

Biological Rationale

PARP enzymes, especially PARP-1, are essential in the base excision repair (BER) pathway of DNA repair. Inhibition of PARP impairs cellular ability to repair single-strand DNA breaks, particularly in cells with defective homologous recombination (HR) such as BRCA1-mutated breast cancer cells (Schwartz 2022). Targeting this vulnerability enables synthetic lethality, a concept where cancer cells dependent on PARP-mediated repair are selectively killed by PARP inhibitors. AZD2461 was developed to exploit this rationale, offering potent PARP-1 inhibition without strong interaction with Pgp, a common efflux transporter responsible for resistance to earlier PARP inhibitors (ApexBio; Related article).

Mechanism of Action of AZD2461

AZD2461 acts as a competitive inhibitor of the NAD+ binding site of PARP-1. This inhibition prevents PARP-1–mediated poly ADP-ribosylation, a post-translational modification critical for recruiting DNA repair proteins. By blocking PARP-1 activity (IC50 = 5 nM, measured in vitro at 25°C, pH 7.4), AZD2461 leads to accumulation of DNA damage, particularly in breast cancer cell lines such as MCF-7 and SKBR-3 (Schwartz 2022). Treated cells show a concentration- and time-dependent reduction in viability, G2 phase accumulation, and reduced S phase entry. In vivo, AZD2461 administration in KB1P tumor-bearing mice causes near-complete PARP inhibition for several hours, with PAR levels normalizing after 24 h (ApexBio). Unlike olaparib, AZD2461 binds poorly to Pgp, improving activity in Pgp-expressing tumors (Related: protocol guide).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 with an IC50 of 5 nM in cell-free assays (25°C, pH 7.4) (ApexBio).
• In MCF-7 and SKBR-3 breast cancer cells, AZD2461 reduces viable cell numbers by >80% at 50 μM after 72 h incubation (Schwartz 2022).
• AZD2461 treatment increases G2 phase and decreases S phase cell populations, indicating G2 arrest (measured by flow cytometry, 48–72 h, 37°C) (Schwartz 2022).
• In vivo studies: AZD2461 (dosed in mice with KB1P tumors) results in prolonged PARP inhibition and extends median relapse-free survival without overt toxicity (Schwartz 2022).
• AZD2461 demonstrates lower affinity for Pgp than olaparib, retaining cytotoxicity in Pgp-overexpressing models (ApexBio).

This article extends prior reviews, such as this in-depth mechanism-focused piece, by explicitly benchmarking cell cycle effects and clarifying resistance profiles not detailed elsewhere.

Applications, Limits & Misconceptions

AZD2461 is primarily used for in vitro and in vivo studies of PARP inhibition in breast and BRCA1-mutated cancers. Experimental concentrations typically range from 5 to 50 μM with 48–72 h incubation. AZD2461 is insoluble in water but soluble in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasonication) (ApexBio). It is suitable for studies on DNA repair, cell cycle, synthetic lethality, and drug resistance mechanisms (Related: translational roadmap).

Common Pitfalls or Misconceptions

• AZD2461 is not effective in water-based solutions: Due to poor water solubility, use DMSO or ethanol as solvents (ApexBio).
• Does not substitute for complete genetic BRCA1 loss: Its synthetic lethality is most pronounced in HR-deficient backgrounds; wild-type HR cells may show reduced sensitivity (Schwartz 2022).
• Long-term solutions are unstable: Prepare fresh solutions for each experiment; do not store working solutions for extended periods (ApexBio).
• Not all Pgp-mediated resistance is overcome: While improved, AZD2461 is not universally active in all multidrug-resistant cell lines (Related protocol guide).
• Not approved for human use: AZD2461 is for research use only; clinical safety and efficacy in humans are unproven.

Workflow Integration & Parameters

For optimal results, dissolve AZD2461 in DMSO or ethanol. Typical working concentrations in cell culture are 5–50 μM. Incubate for 48–72 h at 37°C in appropriate media (pH 7.2–7.4). For in vivo studies, follow dosing regimens validated in KB1P mouse models. Store solid AZD2461 at -20°C. Use fresh solutions; long-term storage of diluted product is not recommended. For detailed troubleshooting and protocol refinements, see AZD2461: Novel PARP Inhibitor Empowering Breast Cancer Research, which summarizes optimization strategies; this article complements those guides by focusing on evidence and mechanistic benchmarks.

Conclusion & Outlook

AZD2461 represents a robust tool for investigating PARP-1 inhibition, DNA repair dynamics, and drug resistance mechanisms in breast cancer research. Its low Pgp affinity and strong efficacy in preclinical models provide a platform for studying relapse-free survival and synthetic lethality. Future research should explore combinatorial regimens and resistance mechanisms in greater molecular detail. For reagent information and ordering, visit the AZD2461 product page.